Cargando…
Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
PURPOSE: The present study was to investigate the real-world efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 83 elderly patients (>65 years) with NSCLC who were progressed at least two li...
Autores principales: | Jiang, Hong-Tao, Li, Wei, Zhang, Biao, Gong, Qiang, Qie, Hai-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572099/ https://www.ncbi.nlm.nih.gov/pubmed/34754233 http://dx.doi.org/10.2147/IJGM.S334436 |
Ejemplares similares
-
Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study
por: Li, Yonghui, et al.
Publicado: (2022) -
Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022) -
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021) -
Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021) -
Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Li, Xiao-Ping, et al.
Publicado: (2022)